Gastrointestinal tract in liver disease: which organ is sick?

被引:47
作者
Norman, Kristina [1 ]
Pirlich, Matthias [1 ]
机构
[1] Charite Univ Med Berlin, Med Klin Gastroenterol Hepatol & Endokrinol, CCM, D-10117 Berlin, Germany
关键词
cachexia syndrome; congestive mucosal changes; gastrointestinal tract; liver disease; portal hypertension; systemic inflammatory response;
D O I
10.1097/MCO.0b013e32830a70bc
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose of review This article gives an overview of the several morphological and functional alterations in the gastrointestinal tract that occur in liver disease and their systemic impact. Recent findings Recent endoscopic studies have revealed similar mucosal alterations in the upper gastrointestinal as well as the colon that include inflammatory-like changes and vascular lesions. Gut-barrier integrity is consequently impaired. There is an evidence that bacterial translocation with subsequent endotoxaemia provokes an inflammatory response that might trigger the cachexia syndrome in liver disease. Novel therapeutic approaches that address gut-barrier function such as supplementation with insulin-like growth factor or synbiotics have shown promising results. Summary There are various alterations of the gastrointestinal tract in liver disease and portal hypertension, which might be less clinically overt than the cardinal potentially life-threatening features, ascites and oesophageal varices. However, these alterations, for example gut-barrier dysfunction and alterations of gut flora (microbiota) have immense impact on the portal enteropathy, as they both contribute to the systemic inflammation in liver cirrhosis, which is considered a risk factor for infections as well as the development of cachexia.
引用
收藏
页码:613 / 619
页数:7
相关论文
共 63 条
[1]   Nutrition and survival in patients with liver cirrhosis [J].
Alberino, F ;
Gatta, A ;
Amodio, P ;
Merkel, C ;
Di Pascoli, L ;
Boffo, G ;
Caregaro, L .
NUTRITION, 2001, 17 (06) :445-450
[2]   Serum lipopolysaccharide-binding protein prediction of severe bacterial infection in cirrhotic patients with ascites [J].
Albillos, A ;
de-La-Hera, A ;
Alvarez-Mon, M .
LANCET, 2004, 363 (9421) :1608-1610
[3]   Tumour necrosis factor-alpha expression by activated monocytes and altered T-cell homeostasis in ascitic alcoholic cirrhosis:: amelioration with norfloxacin [J].
Albillos, A ;
de la Hera, A ;
Reyes, E ;
Monserrat, J ;
Muñoz, L ;
Nieto, M ;
Prieto, A ;
Sanz, E ;
Alvarez-Mon, M .
JOURNAL OF HEPATOLOGY, 2004, 40 (04) :624-631
[4]   Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement [J].
Albillos, A ;
de la Hera, A ;
González, M ;
Moya, JL ;
Calleja, JL ;
Monserrat, J ;
Ruiz-del-Arbol, L ;
Alvarez-Mon, M .
HEPATOLOGY, 2003, 37 (01) :208-217
[5]   Evolutive phases of experimental prehepatic portal hypertension [J].
Aller, Maria-Angeles ;
Nava, Maria-Paz ;
Cuellar, Carmen ;
Chivato, Tomas ;
Arias, Jorge-Luis ;
Sanchez-Patan, Fernando ;
de Vicente, Felipe ;
Alvarez, Emilio ;
Arias, Jaime .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2007, 22 (07) :1127-1133
[6]  
Aprile LRO, 2002, AM J GASTROENTEROL, V97, P3038
[7]   Contribution of ascites to impaired gastric function and nutritional intake in patients with cirrhosis and ascites [J].
Aqel, BA ;
Scolapio, JS ;
Dickson, RC ;
Burton, DD ;
Bouras, EP .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2005, 3 (11) :1095-1100
[8]   Portal hypertensive duodenopathy: Clinical, endoscopic, and histopathologic profiles [J].
Barakat, Maha ;
Mostafa, Mohamed ;
Mahran, Zeinab ;
Soliman, Abdel-Ghani .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 (12) :2793-2802
[9]  
Bauer TM, 2002, AM J GASTROENTEROL, V97, P2364
[10]   Small intestinal bacterial overgrowth in patients with cirrhosis:: Prevalence and relation with spontaneous bacterial peritonitis [J].
Bauer, TM ;
Steinbrückner, B ;
Brinkmann, FE ;
Ditzen, AK ;
Schwacha, H ;
Aponte, JJ ;
Pelz, K ;
Kist, M ;
Blum, HE .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2001, 96 (10) :2962-2967